Apatinib has been reported to be a promising treatment for sorafenib-resistant hepatocellular carcinoma (HCC) patients.
However, the underlying mechanism remains ambiguous.
The study aimed to explore the efficacy of apatinib in sorafenib-resistant HCC and the underlying mechanism both
